Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Epitalon vs MOTS-c

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: it depends on the goal

Epitalon and MOTS-c followed the same regulatory path, and neither has a human trial showing a benefit. Epitalon is graded one step higher (human observational versus animal only) because two Russian studies reported higher melatonin output after the peptide, but their abstracts do not state design or sample size. On regulation, neither is FDA approved or on the 503A bulks list, but both are among the six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription. For both, FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). They differ in what they target. Epitalon is studied for telomeres and life span in cells and mice, mostly by its developing institute; MOTS-c is studied for insulin sensitivity and exercise capacity in mice, with independent human data on blood levels and genetics.

Verified: Verified Oct 28, 2026
EpitalonSponsoredFrom Bodybuilding Peptides
MOTS-cSponsoredFrom Bodybuilding Peptides

Which is better, epitalon or MOTS-c?

Regulatory status does not separate them: both are off the 503A bulks list and both are covered by the same HHS draft enforcement discretion policy, which does not change either evidence grade. Epitalon has the higher grade (human observational versus animal only) on two Russian studies that reported higher melatonin output, but their abstracts do not state the design, the sample size, or whether participants were randomized, and both come from the network that developed the peptide, so the grade says little about benefit. MOTS-c has the more independent and mechanistically detailed research base (AMPK activation, a human genetic variant linked to diabetes, exercise induced blood levels), which makes it the more defensible research interest for metabolic goals. Epitalon's lifespan data come from one mouse study in which mean life span did not change, and the randomized, placebo controlled trial often cited for it tested the pineal extract Epithalamin, not synthetic epitalon. Neither should be expected to produce a clinical benefit. [2] [3] [5] [7] [8] [9] [11] [12] [13]

How do epitalon and MOTS-c compare?

Epitalon and MOTS-c compared by dimension
DimensionEpitalonMOTS-c
Structure [1] [5]Synthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on a bovine pineal extract.16 amino acid peptide encoded naturally by human mitochondrial DNA.
Proposed mechanism [1] [4] [5]Induces telomerase (hTERT) and lengthens telomeres in human cell lines; proposed gene regulation and melatonin effects.Inhibits the folate cycle, raises AICAR, and activates AMPK, increasing muscle glucose uptake and fat oxidation.
Strongest animal result [2] [5] [6]In lifelong female SHR mice, longer life for the longest lived 10% and fewer spontaneous tumors, with no significant change in mean life span.Prevented diet induced obesity and insulin resistance, improved insulin sensitivity in aged mice, and improved running capacity in young and old mice.
Human data [3] [6] [7] [11] [12]Two Russian studies reported higher melatonin output after the peptide; their abstracts do not state design or sample size, and both come from the network that developed it. The randomized, placebo controlled trial often cited tested the pineal extract Epithalamin, not synthetic epitalon.Independent observational data: levels rise with exercise in young men; a MOTS-c sequence variant is associated with type 2 diabetes in Japanese men.
Theoretical safety concern [2] [5]Telomerase activation could in theory support existing tumors, though mice had fewer tumors.Could add to the glucose lowering of diabetes medications, based on mouse data.
Animal study dosing [2] [3] [5] [6]0.1 ug per mouse subcutaneously in monthly 5 day courses; Russian human reports used 10 mg courses of the extract.0.5 mg/kg per day intraperitoneally (metabolic) up to 15 mg/kg (exercise) in mice.
Note: No human dose has been established for either peptide.
Typical cost through a prescriber [8] [9] [13]No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. MOTS-c is covered by the same draft policy as epitalon.
Note: For both, FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). The HHS policy is a draft and is not binding.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Epitalon and MOTS-c: grade, status, and cost
AttributeEpitalonMOTS-c
ClassSynthetic tetrapeptide (Ala-Glu-Asp-Gly) modeled on the bovine pineal extract EpithalaminMitochondrial derived peptide (16 amino acids) encoded in the 12S rRNA region of mitochondrial DNA
What it is4 amino acid peptide from a pineal gland extract: telomere and lifespan data in cells and mice, human melatonin studies of unstated design, not FDA approved.A 16 amino acid peptide coded by mitochondrial DNA that improves metabolism and exercise capacity in mice; human data limited to blood levels and genetics.
EvidenceEvidence: Human observational evidenceEvidence: Animal-only evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: HHS interim policy (draft)
CompoundingEpitalon is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 24, 2026 for insomnia: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds epitalon when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection, in intermittent courses), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add epitalon to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.MOTS-c is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds MOTS-c when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous or intramuscular injection), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. The draft policy is not an FDA approval, does not add MOTS-c to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesSubcutaneous injection (as sold), Intramuscular injection (Russian Epithalamin reports), Intranasal and oral products exist without absorption dataSubcutaneous injection (as sold), Intraperitoneal injection (animal studies)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Last verified

Has epitalon been tested directly against MOTS-c?

No published trial has compared epitalon and MOTS-c directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do epitalon and MOTS-c cost?

Typical cost of Epitalon and MOTS-c
DimensionEpitalonMOTS-c
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient epitalon on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient MOTS-c on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Price detailEpitalon price by channelMOTS-c price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Epitalon page and the MOTS-c page.

Frequently asked questions

Are epitalon and MOTS-c legal to get with a prescription?

Possibly, under conditions, and both have the same status. Neither is FDA approved or on the 503A bulks list, but both are covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding either one as a single-ingredient product on a patient-specific prescription, by subcutaneous or intramuscular injection (for epitalon, in intermittent courses), from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. A combined product is not covered. FDA presented both at its July 23 to 24, 2026 compounding advisory committee meeting; FDA's drug center recommended against listing, and the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. State law still applies. [8] [9] [13] [14]

Which one has better evidence for longevity?

Neither has human evidence for longevity. Epitalon extended life only in the longest lived tenth of female mice without changing mean life span, and MOTS-c improved physical capacity in old mice. Epitalon's human studies measured melatonin output, not life span, and MOTS-c has no human treatment study. [2] [3] [6] [11] [12]

Which is more relevant for blood sugar or weight?

MOTS-c. It prevented diet induced obesity and insulin resistance in mice, and a human genetic variant that weakens it is associated with type 2 diabetes. Epitalon has not been studied for metabolic outcomes. No human treatment trial exists for either. [5] [7]

Are they banned in sport?

Yes. Both are prohibited at all times: epitalon under WADA section S0 as a non-approved substance, and MOTS-c under section S4.4, where it is named as a metabolic modulator. [10]

Conditions studied

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med 2003PubMed 12937682, 2003
  2. [2]Anisimov VN et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology 2003PubMed 14501183, 2003
  3. [3]Khavinson VK, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett 2003PubMed 14523363, 2003
  4. [4]Al-Dulaimi S et al. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology 2025PubMed 40908429, 2025
  5. [5]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab 2015PubMed 25738459, 2015
  6. [6]Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun 2021PubMed 33473109, 2021
  7. [7]Zempo H et al. A pro-diabetogenic mtDNA polymorphism in the mitochondrial-derived peptide, MOTS-c. Aging (Albany NY) 2021PubMed 33468709, 2021
  8. [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA
  9. [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA
  10. [10]WADA Prohibited List (section S0 non-approved substances and section S4.4 metabolic modulators)WADA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Epitalon vs MOTS-c: evidence, cost, and legality. https://peptideagent.ai/compare/epitalon-vs-mots-c
HTML link
<a href="https://peptideagent.ai/compare/epitalon-vs-mots-c">Epitalon vs MOTS-c: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.